YMAB — Y-mAbs Therapeutics Share News
0.000.00%
Last trade - 00:00- $390.32m
- $328.02m
- $87.69m
Brief: Y-mAbs Therapeutics Reports Q4 net income USD 1.2 million
Y-mAbs Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Y-Mabs Therapeutics Has No Cash Deposits Or Securities At Silicon Valley Bank
Y-mAbs Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Y-mAbs Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Y-mAbs up on EMA's nod to pediatric investigation plan for cancer drug
Brief: Y-Mabs Reaches Agreement with EMA On The Pediatric Investigation Plan For Naxitamab
U.S. STOCKS ON THE MOVE-Lamb Weston Foldings, Stitch Fix, Bellerophon Therapeutics
U.S. STOCKS ON THE MOVE-Boxed Inc, Oil companies, Tesla
U.S. STOCKS ON THE MOVE-Walgreens, Silvergate, Bed Bath & Beyond
Y-mAbs Therapeutics falls as 2023 forecast for sole commercial drug disappoints
Brief: Y-Mabs Estimates 35% Reduction Of Workforce As Part Of Restructuring
Brief: Y-Mabs Announces Partnership Regarding Early Access Program For Danyelza (Naxitamab-Gqgk) In Europe
U.S. STOCKS ON THE MOVE-Tesla, Neptune Wellness, Ardelyx
Y-mAbs down as EU regulator recommends against cancer drug
Brief: CHMP Has Adopted A Negative Opinion For Omburtamab For Treatment Of CNS/LM Metastasis From Neuroblastoma In Europe
Brief: Y-Mabs Announces Pipeline Update
Brief: Y-Mabs' Danyelza For Treatment Of High-Risk Neuroblastoma Approved In China